Hikma Pharmaceuticals PLC
Suletud
SektorTervishoid
1,486 0.41
Ülevaade
Aktsiahinna muutus
24h
Min
1480
Max
1487
Sissetulek | 165M |
|---|---|
Müük | 41M 1.7B |
P/E Sektori keskmine | 10.771 49.052 |
Aktsiakasum | 1.07 |
Dividenditootlus | 5.74 |
Kasumimarginaal | 9.698 |
Töötajad | 9,400 |
EBITDA | 152M 411M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +23.99% upside |
Dividenditootlus Sektori keskmine | 5.74% 2.36% |
|---|---|
Järgmine tulemuste avaldamine | 6. aug 2026 |
Järgmine aktsia dividendi kuupäev (ex-date) | 13. aug 2026 |
Turukapital | -526M 3.1B |
|---|---|
Eelmine avamishind | 1485.59 |
Eelmine sulgemishind | 1486 |
Uudiste sentiment
By Acuity
43%
57%
118 / 342 Pingereas Healthcare
Hikma Pharmaceuticals PLC Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.